Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Bristol-Myers Squibb Company (BMY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Bristol-Myers Squibb's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
48.94 +0.63    +1.31%
16:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
48.98
+0.04
+0.08%
19:59:11 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 8,077,202
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 48.12 - 49.05
Bristol-Myers Squibb 48.94 +0.63 +1.31%

Bristol-Myers Squibb Company Company Profile

 
Get an in-depth profile of Bristol-Myers Squibb Company, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

34100

Equity Type

ORD

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Contact Information

Address Route 206 & Province Line Road
Princeton, 08543
United States
Phone 609 252 4621
Fax -

Top Executives

Name Age Since Title
Gerald L. Storch 67 2012 Independent Director
Julia A. Haller 69 2019 Independent Director
Phyllis R. Yale 67 2019 Independent Director
Derica W. Rice 59 2020 Independent Director
Manuel Hidalgo Medina 56 2021 Independent Director
Peter J. Arduini 59 2016 Independent Director
Karen H. Vousden 66 2018 Independent Director
Paula Ann Price 63 2020 Independent Director
Christopher S. Boerner 53 2018 CEO & Chairman
Theodore Rapp Samuels 69 2017 Lead Independent Director
Deepak L. Bhatt 56 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BMY Comments

Write your thoughts about Bristol-Myers Squibb Company
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Imad Bitar
Imad Bitar Apr 09, 2024 7:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
According to Morgan Stanley today, they priced it at 40 to 41, they are either trying to short it or they know something we don’t know, what do y’all think?
Feb 06, 2024 5:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Without having a trusted person to help you make it huge in investing dose sound good to me , my wife just made me happy since morning I haven't been able to keep down the happiness in heart I have nothing to say then God bless you for the payout form the last investment ...his wasp. (+)31612574318). 1001010010101010100101010100101010101010101001010101010101010100101010101010100101010101010101010110101010101001101010101001010101100101101001101001010110100110110010101101010011010100101100101011010101001100101010110
david lee
david lee Feb 06, 2024 10:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this is big sale
david lee
david lee Feb 06, 2024 10:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buying...
Feb 06, 2024 10:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sale to 44
Feb 05, 2024 3:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
Feb 05, 2024 12:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is a stock that must only go up according to all the data and reports!
david lee
david lee Feb 05, 2024 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
big sale...
Feb 05, 2024 11:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
40 dolar
Feb 05, 2024 11:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
big sale
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email